1.Sales and profit
See section β- NewcelX Ltd. lost $8.3M in fiscal 2025.
NewcelX Ltd.
NCEL Nasdaq Pharmaceutical Preparations Financials FY2018βFY2025
Download report
3-page PDF: the company, its results and charts with peers.
KIRAβs summary AI analyst
Hi! I read NewcelX Ltd.βs latest annual report (fiscal 2025). Here is what stands out:
1 strength 3 to watch
2.Cash and shareholders
See section β- Free cash flow was β$2.8M in fiscal 2025, β of revenue.
- No open-market insider trades in the last 12 months.
3.Financial health
See section β- NewcelX Ltd. has $1.8M more cash than debt.
- Its return on capital was β37.5%: every 100 invested in the business earned about β37 in a year.
- NewcelX Ltd. passes 4 of 7 financial health tests (Piotroski F-score).
NewcelX Ltd. in 30 seconds
Good So-so Weak
Weak
Does it make a profit?
β$8.3M
No. It lost money last year.
So-so
How healthy are the accounts?
4 / 7
Mixed. It passes 4 of 7 health tests.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Key numbers, fiscal 2025
Market cap
Last close times the latest diluted share count, so it is approximate.
β
P/E
Last close divided by diluted earnings per share over the last four quarters.
β
On $2.16 EPS (TTM)
Sales and profit
Is it selling more, and how much does it keep?
Results dates
In plain words: Every quarter, companies publish how much they sold and earned. These are the days NewcelX Ltd. did it, and the next one. Share prices often move a lot on those days.
Next results
April 28, 2027
Wednesday Β· in 185 days
- Time
- After the market closes
- Covers
- Period ended Dec 31, 2026
- Source
- Stoqly estimate
Estimated from the same quarter last year. It will be replaced by the announced date once there is one.
See who else reports that week β| Date | Results for | Time | Source |
|---|---|---|---|
| Apr 29, 2026 | Period ended Dec 31, 2025 | After the market closes | 20-F β |
| May 16, 2025 | Period ended Dec 31, 2024 | After the market closes | 20-F β |
| May 15, 2024 | Period ended Dec 31, 2023 | After the market closes | 20-F β |
| May 5, 2023 | Period ended Dec 31, 2022 | After the market closes | 20-F β |
| Mar 24, 2022 | Period ended Dec 31, 2021 | After the market closes | 20-F β |
| May 14, 2021 | Period ended Dec 31, 2020 | After the market closes | 20-F β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
Revenue and margins
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
FY18
Revenue β
FY19
Revenue β
FY20
Revenue β
FY21
Revenue β
FY22
Revenue β
FY23
Revenue β
FY24
Revenue β
FY25
Revenue β
Margins, % of revenue
FY18
Gross β
Operating β
Net β
FCF β
FY19
Gross β
Operating β
Net β
FCF β
FY20
Gross β
Operating β
Net β
FCF β
FY21
Gross β
Operating β
Net β
FCF β
FY22
Gross β
Operating β
Net β
FCF β
FY23
Gross β
Operating β
Net β
FCF β
FY24
Gross β
Operating β
Net β
FCF β
FY25
Gross β
Operating β
Net β
FCF β
Gross
Operating
Net
FCF
Net income and earnings per share
KIRA Β· NewcelX Ltd. lost $8.3M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
FY18
Net income β$5.1M
FY19
Net income β$5.4M
FY20
Net income β$2.9M
FY21
Net income β$11.9M
FY22
Net income β$16.5M
FY23
Net income β$3.3M
FY24
Net income β$7.2M
FY25
Net income β$8.3M
Diluted EPS
FY18
Diluted EPS β
FY19
Diluted EPS β
FY20
Diluted EPS β$0.41
FY21
Diluted EPS β$1.00
FY22
Diluted EPS β$33.52
FY23
Diluted EPS $1.13
FY24
Diluted EPS $2.43
FY25
Diluted EPS $2.16
Cash and shareholders
How much cash comes in, and where does it go?
Cash flow
KIRA Β· Free cash flow was β$2.8M in fiscal 2025, β of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
FY18
Free cash flow β
FY19
Free cash flow β
FY20
Free cash flow β
FY21
Free cash flow β$15.0M
FY22
Free cash flow β
FY23
Free cash flow β$3.5M
FY24
Free cash flow β$1.1M
FY25
Free cash flow β$2.8M
Cash from operations vs capital spending
FY18
Cash from operations β$2.7M
Capital spending β
FY19
Cash from operations β$0.2M
Capital spending β
FY20
Cash from operations β$0.7M
Capital spending β
FY21
Cash from operations β$14.9M
Capital spending $0.0M
FY22
Cash from operations β$13.9M
Capital spending β
FY23
Cash from operations β$3.4M
Capital spending $0.0M
FY24
Cash from operations β$1.1M
Capital spending $0.0M
FY25
Cash from operations β$2.8M
Capital spending $0.0M
Cash from operations
Capital spending
Dividends, buybacks and share count
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
FY18
Dividends β
Buybacks β
FY19
Dividends β
Buybacks β
FY20
Dividends β
Buybacks β
FY21
Dividends β
Buybacks β
FY22
Dividends β
Buybacks β
FY23
Dividends β
Buybacks β
FY24
Dividends β
Buybacks β
FY25
Dividends β
Buybacks β
Dividends
Buybacks
Diluted shares outstanding (annual)
FY18
Diluted shares 0.01B
FY19
Diluted shares 0.01B
FY20
Diluted shares 0.01B
FY21
Diluted shares 0.01B
FY22
Diluted shares 0.00B
FY23
Diluted shares 0.00B
FY24
Diluted shares 0.00B
FY25
Diluted shares 0.00B
Insider trades
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Financial health
Can it carry its debts, and how well does it use its money?
Balance sheet
KIRA Β· NewcelX Ltd. has $1.8M more cash than debt.
Cash, debt and the ratios that show how comfortably NewcelX Ltd. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
FY18
Cash $0.0M
Debt β
FY19
Cash $0.2M
Debt β
FY20
Cash $0.1M
Debt $0.3M
FY21
Cash $5.4M
Debt β
FY22
Cash $8.9M
Debt β
FY23
Cash $1.1M
Debt β
FY24
Cash $0.7M
Debt $7.7M
FY25
Cash $2.2M
Debt $0.4M
Cash
Debt
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $5.4M | $8.9M | $1.1M | $0.7M | $2.2M |
| Debt incl. finance leases | β | β | β | $7.7M | $0.4M |
| Debt / equity | β | β | β | β | 0.0x |
| Interest coverage | β246.6x | β162.6x | β25.1x | β45.8x | β |
| Current ratio | 2.4x | 2.8x | 0.2x | 0.1x | 0.8x |
| Quick ratio | 2.4x | 2.8x | 0.2x | 0.1x | 0.8x |
| Total assets | $5.8M | $9.3M | $1.8M | $0.9M | $11.4M |
| Total liabilities | $5.2M | $6.0M | $10.7M | $8.9M | $4.2M |
| Shareholders' equity | $0.5M | $0.1M | β$1.2M | β$8.0M | $7.3M |
| Net debt (β = net cash) | β | β | β | $7.1M | β$1.8M |
Returns on capital
KIRA Β· Its return on capital was β37.5%: every 100 invested in the business earned about β37 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
FY18
Return on capital β
Return on equity β
Return on assets β
FY19
Return on capital β
Return on equity β
Return on assets β782.2%
FY20
Return on capital β
Return on equity β
Return on assets β299.9%
FY21
Return on capital β
Return on equity β
Return on assets β342.5%
FY22
Return on capital β
Return on equity β5,049.2%
Return on assets β219.3%
FY23
Return on capital β
Return on equity β
Return on assets β59.9%
FY24
Return on capital β
Return on equity β
Return on assets β523.5%
FY25
Return on capital β37.5%
Return on equity β
Return on assets β134.4%
Return on capital
Return on equity
Return on assets
Piotroski F-score
KIRA Β· NewcelX Ltd. passes 4 of 7 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β |
| F-score | β / 3 | β / 4 | β / 6 | β / 6 | β / 6 | β / 6 | β / 6 | 4 / 7 |
| Accruals ratio | β | β754.9% | β223.5% | 85.7% | β34.8% | 2.0% | β446.0% | β89.6% |
| Altman Z'' | β | β201.77 | β131.69 | β33.52 | β27.49 | β156.99 | β351.81 | β24.45 |
All figures
Every number, year by year.
8 years of figures
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Research and development | $0.7M | $0.9M | $0.1M | $5.9M | $9.0M | $1.6M | $1.0M | $1.1M |
| Operating income | β$3.4M | β$4.2M | β$2.3M | β$11.9M | β$15.5M | β$3.0M | β$2.1M | β$2.6M |
| Interest expense | β | $0.0M | $0.1M | $0.0M | $0.1M | $0.1M | $0.0M | β |
| Pretax income | β | β | β | β | β | β$3.3M | β$7.2M | β |
| Net income | β$5.1M | β$5.4M | β$2.9M | β$11.9M | β$16.5M | β$3.3M | β$7.2M | β$8.3M |
| Net income to common | β | β | β | β | β$16.5M | $3.3M | $7.2M | $8.3M |
| Diluted EPS | β | β | β$0.41 | β$1.00 | β$33.52 | $1.13 | $2.43 | $2.16 |
| Diluted shares | 0.01B | 0.01B | 0.01B | 0.01B | 0.00B | 0.00B | 0.00B | 0.00B |
| Cash flow | ||||||||
| Cash from operations | β$2.7M | β$0.2M | β$0.7M | β$14.9M | β$13.9M | β$3.4M | β$1.1M | β$2.8M |
| Capital expenditure | β | β | β | $0.0M | β | $0.0M | $0.0M | $0.0M |
| Free cash flow | β | β | β | β$15.0M | β | β$3.5M | β$1.1M | β$2.8M |
| Depreciation and amortization | β | β | β | $0.0M | $0.0M | $0.6M | $0.4M | $0.1M |
| Stock-based compensation | β | β | β | β | $0.0M | $0.1M | $0.2M | $0.8M |
| Acquisitions | β | β | β | β | β | β | β | β$1.7M |
| Balance sheet | ||||||||
| Cash and short-term investments | $0.0M | $0.2M | $0.1M | $5.4M | $8.9M | $1.1M | $0.7M | $2.2M |
| Total debt | β | β | $0.3M | β | β | β | $7.7M | $0.4M |
| Current assets | β | $0.4M | $0.2M | $5.7M | $9.2M | $1.8M | $0.8M | $3.2M |
| Current liabilities | β | $4.0M | $7.2M | $2.4M | $3.4M | $7.9M | $8.9M | $4.2M |
| Property and equipment, net | β | β | β | $0.0M | $0.0M | $0.0M | $0.1M | $0.1M |
| Goodwill | β | β | β | β | β | β | β | $1.7M |
| Total assets | β | $0.7M | $1.2M | $5.8M | $9.3M | $1.8M | $0.9M | $11.4M |
| Total liabilities | β | $6.9M | $10.2M | $5.2M | $6.0M | $10.7M | $8.9M | $4.2M |
| Preferred stock | β | β | β | β | β | β | $2.7M | β |
| Shareholders' equity | β$8.8M | β$6.2M | β$9.0M | $0.5M | $0.1M | β$1.2M | β$8.0M | $7.3M |
| Returns | ||||||||
| Return on capital | β | β | β | β | β | β | β | β37.5% |
| Return on capital employed | β | 125.7% | 38.4% | β352.9% | β261.7% | 49.6% | 25.8% | β35.3% |
| Return on equity | β | β | β | β | β5,049.2% | β | β | β |
| Return on assets | β | β782.2% | β299.9% | β342.5% | β219.3% | β59.9% | β523.5% | β134.4% |
| Return on tangible equity | β | β | β | β2,202.5% | β14,861.0% | β | β | 150.4% |
| Growth | ||||||||
| EPS growth | β | β | β | β | β | β | 115.0% | β11.1% |
| Share count change | β | 9.6% | 1.8% | 71.0% | β95.9% | 500.5% | 0.1% | 29.9% |
| Financial health | ||||||||
| Debt / equity | β | β | β | β | β | β | β | 0.0x |
| Interest coverage | β | β4,197.0x | β26.5x | β246.6x | β162.6x | β25.1x | β45.8x | β |
| Current ratio | β | 0.1x | 0.0x | 2.4x | 2.8x | 0.2x | 0.1x | 0.8x |
| Quick ratio | β | 0.1x | 0.0x | 2.4x | 2.8x | 0.2x | 0.1x | 0.8x |
| Quality scores | ||||||||
| Piotroski F-score | β | β | β | β | β | β | β | 4.0 |
| Altman Z'' | β | β201.8 | β131.7 | β33.5 | β27.5 | β157.0 | β351.8 | β24.5 |
| Accruals ratio | β | β754.9% | β223.5% | 85.7% | β34.8% | 2.0% | β446.0% | β89.6% |
Source: SEC EDGAR XBRL filings (CIK 0001783036). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.